Clinigen’s (LON:CLIN) Global Access Programs (GAP) arm has extended its distribution agreement with BTG (LON:BTG) subsidiary Protherics Medicines to a third product.
GAP will exclusively manage a named patient programme in 37 European countries for uridine triacetate, used as an antidote to overexposure to the widely used chemotherapy drug 5-fluorouracil (5-FU).
Over 10,000 patients every year across Europe are estimated to be overdosed with 5-FU and although not yet approved in Europe the programme will allow uridine triacetate to be administered to named patients.
Drug developer Wellstat Therapeutics granted named patient supply rights to BTG in Europe in 2012. Clinigen will provide the named patients access to uridine triacetate 24 hours a day, 7 days a week.
Mark Corbett, Clinigen GAP’s senior vice president, said: "We are pleased to be extending our current agreement with BTG to add a third programme to the portfolio already handled by Clinigen.
“5-FU overexposure is an important unmet medical need and making available the supply of uridine triacetate on a named patient basis will provide healthcare professionals access to this investigational antidote to treat patients."